Track record · closed signal

AstraZeneca PLC (AZN) — closed signal from December 3, 2025

Near target Published before the outcome was known, scored automatically when the window closed on March 3, 2026 — +12.5% at the close.

Predicted vs. what happened

AZN price · publication thesis → realized outcomesplit-adjusted
$179.33 Published $418.82 Target $201.76 Window close $210.50 Peak
$344.71 – $360.38Entry zone — fair-value band
$179.33Published — price the day we called it
$418.82Target — the price the thesis aimed for
$210.50Peak — highest point inside the window, not a realized return
$201.76Window close — end-of-window price, context only

What happened

Near target

Came within reach: 97% of the predicted growth at its peak, just short of the target.

At window close
+12.5%
realized, from the publication price to the last close inside the window
Peak gain
+17.4%
peak, from the publication price — not a realized return
S&P 500, same window
-0.2%
SPY over the identical days, dividend-adjusted
Window close
$201.76
last close inside the window, ended March 3, 2026
Peak price
$210.50
peak on February 18, 2026 — not a realized return
Days to target
—

The thesis — published December 3, 2025

Predicted growth
+18%
over the measurement window
Target price
$418.82
the price the thesis aimed for
Entry zone
$344.71 – $360.38
the fair-value band we waited for
Price at publication
$179.33
published December 3, 2025
Confidence
78%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

AstraZeneca looks like a high-quality large drug company that has fallen enough to invite buyers. Signs that selling has slowed and early price improvement make a rebound likely. A major bank named it a top pick and raised its price target to 108.50. New AI pathology work also strengthens the story and improves short-term sentiment.

Primary drivers

  • Stock fell a lot and now shows signs selling may be ending.
  • A top bank picked AZN for 2026 and raised its price target.
  • AI tools for pathology strengthen the company's drug development story.
  • Pharma's defensive nature helps if markets turn down.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All AZN signals